Navigation Links
AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
Date:9/16/2009

for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009, there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United States. To date, several FDA approved therapies exist for the treatment of multiple myeloma. Despite this progress, patients continue to relapse, become refractory to prior treatments and eventually die from their disease. Thus, new therapies are needed to treat these patients and extend their survival.

About Perifosine

Perifosine is a novel oral anti-cancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. Perifosine. is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking stateme
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
2. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
4. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
5. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
6. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
7. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
8. AEterna Zentaris Receives US$10 Million from Institutional Investors
9. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
10. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 ... ), the global specialty biopharmaceutical company, and ArmaGen, ... a worldwide licensing and collaboration agreement for AGT-182, ... potential treatment of both the central nervous system ... syndrome (MPS II). This collaboration strengthens Shire,s rare ...
(Date:7/23/2014)... OncLive® is pleased to announce ... its Strategic Alliance Partnership program. , By ... Lineberger will have the opportunity to work with ... cutting-edge research initiatives, community-directed cancer prevention programs, and ... with OncLive to educate their peers by providing ...
(Date:7/22/2014)... The Board of Directors of BD (Becton, Dickinson ... quarterly dividend of 54.5 cents per common share payable on ... 2014. The indicated annual dividend rate is $2.18 per share. ... leading medical technology company that partners with customers and stakeholders ... health needs. Our innovative solutions are focused on improving drug ...
(Date:7/22/2014)... 22, 2014   BioTE Medical , a ... bio-identical hormone pellets, today announced the addition of ... company.   Dr. Rouzier is joining the BioTE Medical ... Dr. Rouzier was residency trained in Family ... a board certified emergency physician still practicing at ...
Breaking Biology Technology:Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3
... RFID investment wholly on the basis of anticipated savings ... chain are merely deluding themselves. In fact, if a ... means that gross inefficiencies exist in its operations, and ... applying RFID. , ,The benefits of RFID related to ...
... Wis. - When Milwaukee-based coffee chain Stone ... the company chose an emerging tool to enhance customer ... company's technology and marketing director, the blog can bring ... that goes beyond mere press releases or other traditional ...
... business and technology leaders is asking Wisconsin Gov. Jim ... for the Biomedical Technology Alliance (BTA), which ... industry in southeastern Wisconsin. , ,The funding was previously ... 15-1, and endorsed by the Doyle administration, but is ...
Cached Biology Technology:The key to finding RFID's ROI 2The key to finding RFID's ROI 3The key to finding RFID's ROI 4Business blogs increase customer interactions 2Business blogs increase customer interactions 3Business blogs increase customer interactions 4Business blogs increase customer interactions 5Budget axe could cut SE Wisconsin tech alliance funding 2Budget axe could cut SE Wisconsin tech alliance funding 3
(Date:7/23/2014)... commonly found in dead bodies and is used in ... to as the post mortem interval. A report of ... Tamil Nadu is provided for the first time based ... DNA barcoding. This study, significant in forensic investigations was ... . , Chrysomya megacephala is commonly found ...
(Date:7/23/2014)... struggle to deal with ever-growing piles of electronic waste ... just how much there is and where it really ... Science & Technology , their study found that nearly ... into just seven developing countries with major potential ... Knut Breivik and colleagues note that the export from ...
(Date:7/23/2014)... bacterial group called SUP05 will play an increasingly important ... oceans as oxygen minimum zones expand, according to research ... National Academy of Sciences . , University of British ... fjord, Canada,s Saanich Inlet, to chart how microbial community ... study paints a very detailed picture of how SUP05 ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... animal compares males to choose a mate, she can't order ... to rely on external cues that may indicate genetic quality. ... the peacock's tail, as cues that females might use. , ... between male genetic quality and ornament quality can be maintained. ...
... progenitor cells differentiate into cartilage cells when one master ... College of Medicine researchers in a report that appears ... of Sciences. , Skeletons are made of bone and ... stem cell, said Dr. Brendan Lee, associate professor of ...
... into brain cells on a new three-dimensional scaffold of ... living body than any other cell culture system. , ... invention-which may one day replace the ubiquitous Petri dish ... PLoS ONE. Shuguang Zhang, associate director of MIT's Center ...
Cached Biology News:Female pronghorns choose mate based on substance as well as show 2Signaling for cartilage 2MIT creates 3-D scaffold for growing stem cells 2MIT creates 3-D scaffold for growing stem cells 3
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: